Last reviewed · How we verify
Dapagliflozin/Metformin
Dapagliflozin/Metformin is a SGLT2 inhibitor / Biguanide combination Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Type 2 diabetes mellitus. Also known as: Xigduo, Group 1.
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Dapagliflozin/Metformin |
|---|---|
| Also known as | Xigduo, Group 1 |
| Sponsor | AstraZeneca |
| Drug class | SGLT2 inhibitor / Biguanide combination |
| Target | SGLT2 (sodium-glucose cotransporter 2) / AMPK pathway |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This combination leverages two complementary mechanisms: dapagliflozin works by blocking SGLT2 in the proximal tubule, allowing filtered glucose to be excreted in urine rather than reabsorbed, thereby lowering blood glucose independently of insulin. Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity through AMPK activation. Together, they provide additive glycemic control with distinct mechanisms of action.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Gastrointestinal disturbances (nausea, diarrhea)
- Hypoglycemia
- Polyuria
Key clinical trials
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes (PHASE4)
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting. (PHASE1)
- The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapagliflozin/Metformin CI brief — competitive landscape report
- Dapagliflozin/Metformin updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Dapagliflozin/Metformin
What is Dapagliflozin/Metformin?
How does Dapagliflozin/Metformin work?
What is Dapagliflozin/Metformin used for?
Who makes Dapagliflozin/Metformin?
Is Dapagliflozin/Metformin also known as anything else?
What drug class is Dapagliflozin/Metformin in?
What development phase is Dapagliflozin/Metformin in?
What are the side effects of Dapagliflozin/Metformin?
What does Dapagliflozin/Metformin target?
Related
- Drug class: All SGLT2 inhibitor / Biguanide combination drugs
- Target: All drugs targeting SGLT2 (sodium-glucose cotransporter 2) / AMPK pathway
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Xigduo, Group 1
- Compare: Dapagliflozin/Metformin vs similar drugs
- Pricing: Dapagliflozin/Metformin cost, discount & access